血浆sEV miR-660-5p作为颈动脉斑块易损性和术后主要不良心血管事件风险的预测因子

核心信息

  • 论文英文标题: Plasma-derived small extracellular vesicle miR-660-5p as a predictor for carotid plaque vulnerability and postoperative major adverse cardiovascular event risk
  • 期刊: Atherosclerosis Plus
  • 发表年份: 2026
  • DOI: 10.1016/j.athplu.2026.100561
  • PMID/PMCID: 42007427; PMC13091415

研究概览

Building on our previous isolation of plaque-derived small extracellular vesicles (sEVs) from carotid atherosclerotic stenosis (CAS) patients, this study aimed to identify plasma sEV-encapsulated miRNAs that reflect plaque vulnerability and predict clinical outcomes, based on differentially expressed miRNAs identified in sEVs from stable versus vulnerable plaques. Plasma-derived sEV miR-660-5p represents a promising non-invasive biomarker for assessing carotid plaque vulnerability and predicting 3-year MACE risk following carotid endarterectomy, offering potential for improved risk stratification and therapeutic targeting.

核心发现

MiRNA sequencing revealed significant upregulation of miR-660-5p in vulnerable plaque-derived sEVs.

Its expression levels showed a significant positive correlation between matched plaque- and plasma-derived sEVs from the same patient.

Moreover, plasma-derived sEV miR-660-5p levels were independently associated with carotid plaque vulnerability in both validation cohorts, defined either by histopathological criteria (endarterectomy cases) or the clinically validated Plaque-Reporting and Data System (RADS) criteria (stenting cases).

Additionally, elevated plasma-derived sEV miR-660-5p levels were also associated with a higher risk of 3-year post-endarterectomy MACE.

研究设计

CAS patients were retrospectively enrolled into four complementary cohorts: (1) a sequencing cohort (n = 12) for miRNA profiling of plaque-derived sEVs; (2) a discovery cohort (n = 62) to identify candidate plasma-derived sEV miRNAs associated with plaque vulnerability; and (3) validation cohort 1 (n = 180; endarterectomy cases) and (4) validation cohort 2 (n = 326; stenting cases) for validating the diagnostic efficacy of the identified plasma-derived sEV miRNAs.

Candidate miRNAs were quantified using a High-throughput nano-bio chip integrated system (HNCIB).

Their associations with plaque vulnerability and 3-year post-endarterectomy major adverse cardiovascular events (MACE) were analyzed.

Echo Biotech 角色

Exosupur排阻柱分离斑块组织和血浆EV，斑块组织外泌体miRNA测序分析

关联平台: Exoomics®, Research Reagents & Tools

关联服务与能力: Biofluid EV Isolation & Purification, Tissue EV Isolation & Purification, EV miRNA Profiling / Sequencing, Research Reagent / Product Supply

关联产品或试剂: Exosupur® EV Isolation/Purification Kit

参考文献

原始论文: Plasma-derived small extracellular vesicle miR-660-5p as a predictor for carotid plaque vulnerability and postoperative major adverse cardiovascular event risk Atherosclerosis Plus. 2026. DOI: 10.1016/j.athplu.2026.100561. PMID/PMCID: 42007427; PMC13091415.